Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (8469)	1/25/1999 10:26:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Just a reminder of the importance of what you have told us. In 1996 Centoxin was turned down for approval in the U.K. Here is cut and paste on this drug. Source is Giroir, in Lancet correspondence. "In another trial in 269 patients with meningococcal sepsis HA-1A reduced mortality by 30% (p<0·08).5" Think this demonstrates why XOMA would continue the trial to assure it has a better chance to gain approval, since p<0.08 with a 305 reduction in mortality was not considered sufficient in the past.

To: Cacaito who wrote (8469)	1/25/1999 6:17:00 PM
From: Robert S.	Respond to of 17367

I guess what it boils down to is that you are viewing circumstances through an optimistic eye, wheresas I am looking at prospects through a skeptical orb. Interesting approach to designing protein drugs: forbes.com

To: Cacaito who wrote (8469)	2/3/1999 2:18:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

From XOMA: They are at 350 accrued. And .. It's a two > armed trial: placebo and treatment (all one dosing regimen) but the > severity scores are stratified: 8-12 and 12-15 in order to keep track of > probable differences in rates between those two populations. Assumption is > that mortality gets higher the higher the GMSPS score.) >